Meeting
2016 ASCO Annual Meeting
miR-125a-induced cellular switch to elicit a response to anti-HER2 targeted therapy in gastric cancer cells.
Authors
Elad Hikri
Sackler Faculty Of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Elad Hikri , Lihi Ninio-Many , Salomon M. Stemmer , Ruth Shalgi , Irit Ben-Aharon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4055)
DOI
10.1200/JCO.2016.34.15_suppl.4055
Abstract #
4055
Poster Bd #
47
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.
First Author: Aranzazu Fernandez-Martinez
Poster
2018 ASCO Annual Meeting
Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.
First Author: Zongbi Yi
Poster
2017 Gastrointestinal Cancers Symposium
Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC).
First Author: Ivonne Haffner
Poster
2016 ASCO Annual Meeting
Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.
First Author: Christian M. Kurbacher